GlassScriptPhysician profile
Jim Amerian
NPI 1366400194
$1,946.08
in general payments reported to CMS, 2019-2025
24 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.90 · 2020: $46.94 · 2021: $12.40 · 2022: $72.11 · 2023: $281 · 2024: $707 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $328.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $278.44 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $156.65 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.05 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $131.97 | 2024-2025 | |
| Janssen Biotech, INC. | $129.27 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ironwood Pharmaceuticals, INC | $104.07 | 2022-2024 | Linzess |
| Abbvie INC. | $92.57 | 2019-2025 | |
| Exact Sciences Corporation | $82.46 | 2023 | Cologuard Collection Kit |
| Qol Medical, LLC | $72.47 | 2025 | Sucraid |
| Genzyme Corporation | $70.84 | 2024-2025 | |
| Novo Nordisk INC | $44.34 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $39.21 | 2023-2024 | |
| Fujifilm Healthcare Americas Corporation | $35.00 | 2024 | Utaswako Afp-L3 |
| Aimmune Therapeutics, INC. | $33.57 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $30.19 | 2024 | Lumera 700 |
| Braintree Laboratories, INC. | $28.26 | 2021-2022 | |
| Ardelyx, INC. | $26.42 | 2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $25.78 | 2025 | Iqirvo |
| Lilly USA, LLC | $23.20 | 2024 | Omvoh |
| Mirum Pharmaceuticals, INC. | $21.83 | 2024 | Livmarli |
| Nevro Corp. | $21.04 | 2023 | Senza |
| Celgene Corporation | $20.92 | 2023 | Zeposia |
| Evoke Pharma, INC. | $17.30 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Amerian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.